JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.99 CNY | +1.52% |
|
+2.74% | -3.54% |
| Apr. 18 | Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint | MT |
| Apr. 18 | Joincare Pharmaceutical Successfully Completes TG-1000 Phase III Study | CI |
| Sales 2024 * | 17.39B 2.4B | Sales 2025 * | 19.01B 2.62B | Capitalization | 22.38B 3.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.52B 209M | Net income 2025 * | 1.74B 240M | EV / Sales 2024 * | 1.29 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.18 x |
| P/E ratio 2024 * |
14.7
x | P/E ratio 2025 * |
12.9
x | Employees | 14,365 |
| Yield 2024 * |
1.54% | Yield 2025 * |
1.75% | Free-Float | 49.39% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.52% | ||
| 1 week | +2.74% | ||
| Current month | +10.10% | ||
| 1 month | +7.63% | ||
| 3 months | +4.17% | ||
| 6 months | +5.27% | ||
| Current year | -3.54% |
1 week
11.58
12.00
1 month
10.7612.00
Current year
9.7012.90
1 year
9.7013.95
3 years
9.7017.60
5 years
7.5122.47
10 years
4.8530.02
| Managers | Title | Age | Since |
|---|---|---|---|
Xiong Yu
PSD | President | 63 | 21-08-26 |
Qing Feng Qiu
DFI | Director of Finance/CFO | 53 | 12-08-27 |
Zhi Wei Xing
BRD | Director/Board Member | 38 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bao Guo Zhu
FOU | Founder | 62 | 92-12-17 |
Xiong Yu
PSD | President | 63 | 21-08-26 |
Jin Hua Peng
BRD | Director/Board Member | 62 | 12-08-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 2 M€ | -18.13% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 11.99 | +1.52% | 10,876,880 |
| 24-04-24 | 11.81 | +0.94% | 7,831,856 |
| 24-04-23 | 11.7 | -0.51% | 9,327,630 |
| 24-04-22 | 11.76 | +1.20% | 11,971,020 |
| 24-04-19 | 11.62 | -0.43% | 9,052,376 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotes
Joincare Pharmaceutical Group Industry Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals and healthcare products. The Company's products include chemical materials and intermediates, chemical agents, health products, traditional Chinese medicines, diagnostic reagents and equipment. The Company is also engaged in electricity business. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.99
CNY
Average target price
14.31
CNY
Spread / Average Target
+19.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.54% | 3.09B | |
| +25.56% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.94% | 233B | |
| +5.33% | 201B | |
| -9.90% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 600380 Stock
